Cancer Research Breakthroughs Archives - NFCR

Cancer Research Breakthroughs

Crizotinib Plus Radiation May Reduce NF2-Related Hearing Loss

A study co-authored by National Foundation for Cancer Research Fellow Dr. Rakesh Jain hints that adding the cancer drug crizotinib to the radiation therapy for tumors associated with neurofibromatosis 2 (NF2) may lessen the hearing loss that often precipitates from radiotherapy. Although not a cancer, NF2 is characterized by benign…...

Read more

Targeted Lung Cancer Therapy

A Match Made Possible A discovery by a team led by Massachusetts General Hospital’s Daniel Haber, M.D., Ph.D., a physician-scientist supported by the National Foundation for Cancer Research since 2003, now represents a source of hope for many patients with metastatic lung cancer. He and his colleagues correctly linked very…...

Read more

Liquid Biopsy Advances: Capturing Metastatic Cancer Cells

A novel instrument for detecting cancer cells in the blood could lead to individualized cancer treatments for patients suffering metastasis. Developed by a Massachusetts General Hospital team led by Daniel Haber, M.D., Ph.D., a renowned cancer scientists supported by the National Foundation for Cancer Research since 2003, the business card-sized…...

Read more

Dr. Doug Lowy on the Future of Cancer Research

Dr. Lowy, in collaboration with Dr. John Schiller, has been awarded the 2018 Szent-Györgyi prize for Progress in Cancer Research for their development of a preventive vaccine for human papilloma virus, which is the leading cause of cervical cancer cases. See why Dr. Lowy thinks that the problems with cancer…...

Read more

Artemisinin Therapies: Connecting the Dots

You wouldn’t think it, but the science cannot be denied: One of the newest and most promising drug candidates for cancer was actually developed all the way back in 1972. For malaria. “There were some hints in the literature, but we were totally ignorant,” admits Curt Civin, M.D., whose work…...

Read more

Szent-Györgyi Prize Winner Profile Series: Peter Vogt: The Game Changer

The term “game changer” didn’t come into English usage until 1993, and since then it has been driven into the ground from overuse. But when applied to Dr. Peter Vogt, it is more than just hyperbole or overzealous marketing. When you are talking about the person that identified src, the…...

Read more

The Development of Better Ovarian Cancer Biomarkers

“The trouble with ultrasound is that it doesn’t detect many ovarian cancers early,” says Robert Bast, M.D., Vice President for Translational Research at MD Andersen Cancer Center in Houston. Moreover, “Ultrasound doesn’t see really small cancers in the ovary.”...

Read more

Pediatric Cancer Drug Has 93 Percent Effectiveness

A new cancer drug, larotrectinib, has in a very early clinical trial been shown to have a 93% (14/15) effectiveness rate for pediatric cancers; that is to say, for not just one cancer, but many. Hailed by the U.S. Food and Drug Administration as a “breakthrough therapy,” larotrectinib targets a…...

Read more

The Role of Micronutrients in Battling Cancer

It was largely the work of Helmut Sies, M.D., the esteemed pioneer of oxidative stress whom the National Foundation for Cancer Research (NFCR) supported from 1983 to 2016, that brought the role of micronutrients, including flavonoids, into scientific focus....

Read more

Master Switch Metastasis Agent Identified

In a major breakthrough, scientists led by Elena Deryugina at The Scripps Research Institute (TSRI) identified a specific protein, Latent TGFβ Binding Protein 3—LTBP3 for short—that kicks off a cellular chain reaction resulting in early-development tumors growing new blood vessels. These vessels then act like highways to spread cancer cells…...

Read more